Cart
sales@molnova.com
Dehydroabietic acid
CAS No. 1740-19-8
Dehydroabietic acid( —— )
Catalog No. M18122 CAS No. 1740-19-8
Dehydroabietic acid (DAA) is an EBV-EA activation inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 59 | In Stock |
|
| 2MG | 33 | In Stock |
|
| 5MG | 52 | In Stock |
|
| 10MG | 92 | In Stock |
|
| 25MG | 174 | In Stock |
|
| 50MG | 257 | In Stock |
|
| 100MG | 369 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 871 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDehydroabietic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionDehydroabietic acid (DAA) is an EBV-EA activation inhibitor.
-
DescriptionDehydroabietic acid (DAA) is an EBV-EA activation inhibitor. DAA is a useful food-derived compound for treating obesity-related diseases, by decreasing plasma glucose, insulin levels, plasma triglyceride (TG) , and hepatic TG levels. DAA derivatives displays anti-secretory and anti-pepsin effect in animal models.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEBV
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number1740-19-8
-
Formula Weight300.44
-
Molecular FormulaC20H28O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (332.85 mM)
-
SMILESCC(C)C1=CC2=C(C=C1)C3(CCCC(C3CC2)(C)C(=O)O)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
PD153035 hydrochlori...
PD153035 hydrochloride (ZM 252868; AG 1517) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM; little effect against PGDFR, FGFR, CSF-1, InsR and Src.
-
Lapatinib
A reversible, selective dual tyrosine kinase inhibitor of both EGFR and ErbB2 with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
-
Anlotinib
Anlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.
